Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GE Healthcare to Acquire PAA Laboratories, GmbH

By Pharmaceutical Processing | August 16, 2011

 

 

GE Healthcare, a unit of General Electric Company,
today announced it has reached an agreement to acquire PAA Laboratories, a developer
and supplier of cell culture media for biomedical research and the fast-growing
biopharmaceutical and vaccine manufacturing industry. The acquisition of PAA
Laboratories will allow GE Healthcare to expand its offering of products and
services for cell biology research and for the discovery and manufacture of
biopharmaceuticals including recombinant proteins, antibodies and vaccines. The
strong strategic fit between the two businesses, combined with expanded capabilities
in product development and marketing, will offer significant long-term customer
benefits. Financial terms were not disclosed.

 

PAA Laboratories develops and manufactures specialized and
innovative cell culture products such as media, sera, growth supplements and reagents
for use in biomedical research and in the production of protein-based pharmaceuticals.
The company, which has world-class manufacturing facilities registered with the
FDA, has recently implemented one of the world’s leading manufacturing
facilities for powdered cell culture media to meet the growing demand for these
products from the biopharmaceutical industry. PAA Laboratories’ products are
complementary to GE Healthcare’s established technologies for cell biology
research and biopharmaceutical purification.

 

Combining the expertise of the two companies will enable GE
Healthcare to offer a substantially wider range of integrated products and services
to the biopharmaceutical manufacturing industry.

 

“The acquisition of PAA Laboratories is a significant
step forward for our Life Sciences business and for biopharmaceutical
manufacturing globally,” said Kieran Murphy, President and CEO of GE
Healthcare Life Sciences. “GE Healthcare Life Sciences is well known for
its expertise in the “downstream” processes of biopharmaceutical
manufacturing.

 

Adding “upstream” capabilities will enable us to
provide an end-to-end, fully integrated service to our customers. We believe
that an integrated approach, where we can help customers optimize every stage
of their manufacturing process, has the potential to reduce cost of entry,
deliver higher yields of finished product and reduce time to market.” The
global demand for media, sera and reagents for cell culture is predicted to
grow from $2.3 billion in 2009 to an estimated $3.9 billion by 2015*. The
acquisition of PAA Laboratories is consistent with GE’s strategy to invest in
high-technology, innovative businesses that deliver strong top-line growth and
expanded margins. The acquisition also supports GE healthymagination, GE’s
global initiative to reduce cost, increase access and improve the quality of
healthcare worldwide.

 

Welcoming the acquisition, Rainer Burian, long-term CEO, PAA
Laboratories said, “This is a great opportunity for the professional team
of staff at PAA Laboratories and we are very excited to become part of GE
Healthcare’s Life Sciences business. The Board of Directors of PAA Laboratories
strongly believes that joining such a well-respected and recognized
organization will give us significant opportunities to grow our business
further with new technologies, products and services. The entire PAA
Laboratories team looks forward to joining GE.”  

 

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE